Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775943 | 0.88 | CYP1A2 (0.60) | ALDH1A1LMNASMN1; SMN2CYP1A2MAPK9 | |
| SCHEMBL27851135 | 0.85 | DHODH (0.47) | GLSALDH1A1HTTCYP1A2MAPK8 | |
| SCHEMBL3720399 | 0.84 | KDM4E (0.59) | GLSALDH1A1HTTLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3712126 | 0.83 | KDM4E (0.57) | GLSALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL29456254 | 0.79 | MAPK8 (0.45) | ALDH1A1LMNACYP1A2MEN1KMT2A | |
| SCHEMBL6902980 | 0.79 | MAPK8 (0.45) | ALDH1A1LMNACYP1A2MEN1KMT2A | |
| SCHEMBL28200282 | 0.79 | MEN1 (0.50) | GLSALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL3782315 | 0.78 | MAPK8 (0.46) | CYP1A2MAPK8MAPK9MAPK10KDM4E | |
| SCHEMBL3136413 | 0.77 | KDM4E (0.56) | GLSALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL1515657 | 0.77 | KDM4E (0.44) | ALDH1A1CYP1A2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102321468-A | Cationic iridium complex phosphorescene probe as well as preparation method and application thereof | UNIV SHANGHAI | 2012-01-18 | — | — | CN | claimed |
| CN-1330657-C | Piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | CN | claimed |
| CN-1451009-A | Glucocortiocoid-selective antinflammatory agents | ABBOTT LAB (US) | 2003-10-22 | — | — | CN | claimed |
| CN-1119348-C | glucocorticoid derivatives, compositions and uses thereof | ABBOTT INC (US) | 2003-08-27 | — | — | CN | claimed |
| CN-1434827-A | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | claimed |
| EP-1299392-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | Abbott Laboratories (US) | 2003-04-09 | — | — | EP | claimed |
| EP-1242427-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | claimed |
| WO-2002002565-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2001046200-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| CN-1296486-A | Glucocorticoid-selective anti-inflammatory agents | ABBOTT LAB (US) | 2001-05-23 | — | — | CN | claimed |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| EP-2782570-B1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190231751-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | IMAGO PHARMACEUTICALS, INC. | 2019-08-01 | — | — | US | disclosed |
| US-20190194176-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| CN-1119348-C | glucocorticoid derivatives, compositions and uses thereof | ABBOTT INC (US) | 2003-08-27 | — | — | CN | disclosed |
| CN-1436232-A | Variants with altered properties | NOVOZYMES AS (DK) | 2003-08-13 | — | — | CN | disclosed |
| CN-1434827-A | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| CN-1422953-A | Gene sequence of Japanese shistosome China mainland strain gynecophoric canal protein | SHANGHAI DOMESTIC ANIMAL PARAS (CN) | 2003-06-11 | — | — | CN | disclosed |
| CN-1296486-A | Glucocorticoid-selective anti-inflammatory agents | ABBOTT LAB (US) | 2001-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194176-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | GLS 1841/4885ALDH1A1 4529/4885HTT 987/4885 |
| US-20190231751-A1 | TREATMENT OF FIBROTIC DISORDERS WITH JUN N-TERMINAL KINASE INHIBITORS | MAP3K20, MYLK2, MAP3K8 | GLS 242/4885ALDH1A1 4182/4885HTT 3501/4885 |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | GLS 1841/4885ALDH1A1 4529/4885HTT 987/4885 |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | GLS 1841/4885ALDH1A1 4529/4885HTT 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.